Bank hails Zealand Pharma's data as "home run"

Danske Bank is very pleased with Zealand Pharma’s concluded phase III study of a short bowel syndrome treatment candidate, raising the company’s share price target and predicted chance of ultimate success.

Photo: Zealand Pharma / PR

Zealand Pharma’s successful phase III trial of glepaglutide, a potential short bowel syndrome treatment, has been met with enthusiasm from analysts, including those at Danske Bank, which describes the study as nothing short of a ”home run” in a note.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs